Belantamab mafodotin is in clinical development for the treatment of multiple myeloma (MM) in patients who are refractory or have relapsed to prior treatments. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of red and white blood cells and platelets. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).
Belantamab mafodotin is a first-in-class therapy delivered via intravenous infusion. This medicine is an antibody drug conjugate comprising a B cell maturation antigen (BCMA)-targeting monoclonal antibody that delivers a cytotoxin (cysMMAF) to abnormal plasma cells, which interferes with the cell’s ability to divide and grow and encourages the immune system to attack the affected cells, slowing the progression of the disease. If licensed, belantamab mafodotin has the potential to improve outcomes in patients that have already received prior treatments but their myeloma has come back.
Brigatinib is a medicinal product that is being developed for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease have progressed following treatment with alectinib or ceritinib. NSCLC is the most common type of lung cancer although a small proportion of NSCLC patients have a rearrangement in the ALK gene. Locally advanced or metastatic cancer means cancer has spread outside the lungs where it started, to other parts of the body and cannot be cured. Current treatment with drugs such as alectinib or ceritinib are effective in slowing the disease and helping patients to live longer, although some patients eventually develop treatment resistance and will require other therapies.